With a market cap of $150.5 billion, Stryker Corporation (SYK) is a leading global medical technology company headquartered in Kalamazoo, Michigan. Founded in 1941, the company has a presence in over 75 countries and a workforce of approximately 53,000 employees.

This healthcare titan’s shares have outpaced the broader market over the past 52 weeks. Stryker has gained 18% over this time frame, while the broader S&P 500 Index ($SPX) has soared 12.5%. Additionally, SKY shares are up 9.5% on a YTD basis, surpassing SPX’s 1.3% rise during the same time frame.

Taking a closer look, SYK has outperformed the Health Care Select Sector SPDR Fund’s (XLV) 8.9% fall over the past 52 weeks and a 3.3% dip on a YTD basis. 

On May 1, Stryker Corporation reported robust first-quarter earnings, and its shares rose 1.1% in the next trading session. Its net sales increased 11.9% year-over-year to $5.9 billion, and adjusted earnings grew 13.6% to $2.84 per share, both of which exceeded the market expectations. Organic net sales grew by 10.1%, driven primarily by a 9.4% rise in unit volume and a marginal increase in pricing. 

For the current fiscal year, ending in December, analysts expect Stryker’s EPS to grow 9.6% year over year to $13.36. The company’s earnings surprise history is promising. It beat the Wall Street estimates in each of the last four quarters. 

Among the 28 analysts covering the stock, the consensus rating is a “Strong Buy,” which is based on 19 “Strong Buy,” two “Moderate Buy,” and seven “Hold” ratings.

On May 5, Truist Securities raised its price target on Stryker from $390 to $400 while maintaining a “Hold” rating. The analyst noted that Stryker achieved strong double-digit growth in both organic sales and EPS, despite facing $200 million in additional tariff headwinds. 

The mean price target of $430.73 represents a 9.3% upside from Stryker’s current price levels, while the Street-high price target of $465 suggests an upside potential of 18%.